A Double-blind Study of the Pharmacokinetic Properties of BIOD-238 and BIOD-250 Compared to Humalog® in Subjects with Type 1 Diabetes
The purpose of this study is to assess the speed of absorption of BIOD-238 and BIOD-250 compared to Humalog®. Secondary objectives are to assess other pharmacokinetic characteristics of BIOD-238 and BIOD-250 compared to Humalog®, and to evaluate the safety and tolerability of BIOD-238 and BIOD-250 compared to Humalog®.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
12
Time to 1/2 maximal insulin concentration
Time frame: 480 minutes
Time to maximal insulin concentration
Time frame: 480 minutes
Time to 1/2 maximal insulin concentration after peak
Time frame: 480 minutes
Visual analog scale
Time frame: 30 minutes
AUC 0-30 and AUC 0-60
Time frame: 60 minutes
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.